Breathe Well Live Well
Danbury News Times |
Boehringer Ingelheim's asthma drug wins FDA approval
Danbury News Times DANBURY — Nearly one in 10 adults in Connecticut – 9.2 percent – has asthma. Boehringer Ingelheim, the Danbury-based pharmaceutical company cited the figure as it announced the federally approved availability of its new Spiriva Respimat product for … Spiriva Respimat Now Available in Pharmacies for Asthma Patients |
View full post on asthma – Google News
|
German firm Boehringer Ingelheim's patent for asthma drug revoked
Economic Times MUMBAI: India's Patent Office has revoked a patent on asthma drug, Spiriva (tiotropium bromide monohydrate) held by German major Boehringer Ingelheim on an opposition filed by generic company, Cipla. The patent was revoked on grounds that it lacks … |
View full post on asthma – Google News
|
Boehringer Ingelheim's tiotropium shows promising results in patients with …
News-Medical.net Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of tiotropium in asthma. These data were presented at the American Thoracic Society … Phase III results: tiotropium* Respimat® effective in symptomatic asthma … Boehringer Ingelheim reports positive data from symptomatic asthma trials |
View full post on asthma – Google News
|
New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA …
News-Medical.net These were the main findings from a new subset of data from the Phase III UniTinA-asthma® programme presented for the first time today at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic … |
View full post on asthma – Google News